This is the authors' abstract. We don't add key points for this paper.
AIM: To determine whether hepatitis C virus (HCV) core substitutions play a role in the response to interferon-based treatment in Caucasian patients. METHODS: gene rs12979860 (Custom TaqMan 5' allelic discrimination assay; Applied Biosystems). CONCLUSION: HCV core mutations can help distinguish between patients who can still benefit from the affordable IFN-based therapy from those who must be treated with DAAs to prevent the evolution towards end-stage liver disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sultana et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: